Protagonist Therapeutics (PTGX) moved 5.7% higher as investors bought into a broad biotech rally, with the stock participating in a sector wide rotation into biotechnology rather than reacting to company specific headlines.

With Protagonist Therapeutics trading at US$140.91 and logging a 24.85% 1 month share price return and 61.63% year to date share price return, the strong 1 year total shareholder return of 153.98% and very large 3 year total shareholder return point to momentum that investors currently associate with improving growth expectations and a changing view of risk around the pipeline.

If you are looking for other ideas in high growth areas, this is a good moment to see what else is moving and check out 39 healthcare AI stocks

Bulls see Protagonist Therapeutics as a high growth pipeline story that justifies a richer price, while bears point to losses and a hot chart. Which case holds up when this move is compared against valuation?

Preferred Price to Book Multiple of 13.8x: Is It Justified?

On Simply Wall St's numbers, Protagonist Therapeutics screens as good value on a DCF basis yet looks expensive on its preferred multiple, which is a P/B ratio of 13.8x, relative to much of the US Biotechs industry.

The P/B ratio compares the company’s market value with its book value, which for a biotech like Protagonist Therapeutics mainly reflects accumulated capital on the balance sheet rather than an established earnings stream. A higher P/B can signal that investors are placing a premium on the pipeline, revenue growth profile or expectations for future profitability that are not yet fully visible in current financials.

Here the contrast is clear. Protagonist Therapeutics is described as trading at 65.9% below an internal fair value estimate based on future cash flows, yet the 13.8x P/B is well above the 2.6x industry average and still only looks reasonable when compared with a peer average P/B of 17.1x. That combination suggests the market is paying a premium price for balance sheet capital relative to the broader biotech group while still not pricing the stock near the higher DCF fair value implied by the SWS model.

Result: Price-to-book of 13.8x (OVERVALUED)

However, Protagonist Therapeutics still faces key risks, including its ongoing net loss of US$114.711 million and the possibility that pipeline trial outcomes or timelines may not meet current expectations.

Another View: DCF Puts Protagonist Therapeutics in a Different Light

While the 13.8x P/B ratio makes Protagonist Therapeutics look expensive against the wider US Biotechs group, the SWS DCF model points in the opposite direction. On those cash flow assumptions, the stock price of $140.91 sits well below an indicated value of $413.64. This raises the question of which signal should carry more weight for you right now.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Protagonist Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 47 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment around Protagonist Therapeutics clearly mixed, this is a good time to review the data yourself and decide how you feel about its risk reward trade off. To help weigh both sides of that equation, start with the 2 key rewards and 1 important warning sign.

Looking For More Investment Ideas Beyond Protagonist Therapeutics?

If Protagonist Therapeutics has you thinking about where capital could work harder next, it is worth scanning other opportunities before this phase of market interest moves on.

• Target potential mispricings by reviewing companies that screen as attractively valued using the 47 high quality undervalued stocks.
• Strengthen your income stream by focusing on stocks with robust yields and balance sheets through the 8 dividend fortresses.
• Get ahead of the crowd by searching for quality companies that are still off most radars with the screener containing 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.